Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Phase II trial of induction chemotherapy with carboplatin AUC 6 plus paclitaxel 175 mg/m2 in
a 21 day cycle for two cycles followed by radiotherapy 4500 cGy in 25 fractions plus
carboplatin AUC=2 paclitaxel 50 mg/m2 in a week regimen followed by minimally invasive
surgery after 6 to 10 weeks. A PET scan will be performed at the time of randomization and 14
days after de first cycle to determine the relation between metabolic response and survival.